GH and the cardiovascular system: an update on a topic at heart

Jörgen Isgaard, Michele Arcopinto, Kristjan Karason, Antonio Cittadini, Jörgen Isgaard, Michele Arcopinto, Kristjan Karason, Antonio Cittadini

Abstract

In this review, the importance of growth hormone (GH) for the maintenance of normal cardiac function in adult life is discussed. Physiological effects of GH and underlying mechanisms for interactions between GH and insulin-like growth factor I (IGF-I) and the cardiovascular system are covered as well as the cardiac dysfunction caused both by GH excess (acromegaly) and by GH deficiency in adult hypopituitary patients. In both acromegaly and adult GH deficiency, there is also increased cardiovascular morbidity and mortality possibly linked to aberrations in GH status. Finally, the status of the GH/IGF-I system in relation to heart failure and the potential of GH as a therapeutic tool in the treatment of heart failure are reviewed in this article.

References

    1. Sacca L, Cittadini A, Fazio S. Growth hormone and the heart. Endocr. Rev. 1994;15:555–573.
    1. Ren J, Samson WK, Sowers JR. Insulin-like growth factor I as a cardiac hormone: physiological and pathophysiological implications in heart disease. J. Mol. Cell. Cardiol. 1999;31:2049–2061.
    1. Sverrisdóttir Y, Elam M, Bengtsson B-Å, Johannsson G. Intense sympathetic nerve activity in adults with hypopituitarism and untreated growth hormone deficiency. J. Clin. Endocrinol. Metab. 1998;83:1881–1885.
    1. Isgaard J, Nilsson A, Vikman K, Isaksson OG. Growth hormone regulates the level of insulin-like growth factor-I mRNA in rat skeletal muscle. J. Endocrinol. 1989;120:107–112.
    1. D’Ercole AJ, Stiles AD, Underwood LE. Tissue concentrations of somatomedin C: further evidence for multiple sites of synthesis and paracrine or autocrine mechanisms of action. Proc. Natl. Acad. Sci. USA. 1984;81:935–939.
    1. Delafontaine P, Bernstein KE, Alexander RW. Insulin-like growth factor I gene expression in vascular cells. Hypertension. 1991;17:693–699.
    1. Mathews LS, Enberg B, Norstedt G. Regulation of rat growth hormone receptor gene expression. J. Biol. Chem. 1989;264:9905–9910.
    1. Isgaard J, Wåhlander H, Adams MA, Friberg P. Increased expression of growth hormone receptor mRNA and insulin-like growth factor-I mRNA in volume-overloaded hearts. Hypertension. 1994;23:884–888.
    1. Wickman A, Friberg P, Adams MA, Matejka GL, Brantsing C, Guron G, Isgaard J. Induction of growth hormone receptor and insulin-like growth factor-I mRNA in aorta and caval vein during hemodynamic challenge. Hypertension. 1997;29:123–130.
    1. Guler HP, Zapf J, Scheiwiller E, Froesch ER. Recombinant human insulin-like growth factor I stimulates growth and has distinct effects on organ size in hypophysectomized rats. Proc. Natl. Acad. Sci. USA. 1988;85:4889–4893.
    1. Wickman A, Isgaard J, Adams MA, Friberg P. Inhibition of nitric oxide in rats. Regulation of cardiovascular structure and expression of insulin-like growth factor I and its receptor messenger RNA. J. Hypertens. 1997;15:751–759.
    1. Pete G, Hu Y, Walsh M, Sowers J, Dunbar JC. Insulin-like growth factor-I decreases mean blood pressure and selectively increases regional blood flow in normal rats. Proc. Soc. Exp. Biol. Med. 1996;213:187–192.
    1. Walsh MF, Barazi M, Pete G, Muniyappa R, Dunbar JC, Sowers JR. Insulin-like growth factor I diminishes in vivo and in vitro vascular contractility: role of vascular nitric oxide. Endocrinology. 1996;137:1798–1803.
    1. Donath MY, Jenni R, Brunner HP, Anrig M, Kohli S, Glatz Y, Froesch ER. Cardiovascular and metabolic effects of insulin-like growth factor I at rest and during exercise in humans. J. Clin. Endocrinol. Metab. 1996;81:4089–4094.
    1. Donath MY, Sutsch G, Yan XW, Piva B, Brunner HP, Glatz Y, Zapf J, Follath F, Froesch ER, Kiowski W. Acute cardiovascular effects of insulin-like growth factor I in patients with chronic heart failure. J. Clin. Endocrinol. Metab. 1998;83:3177–3183.
    1. Manelli F, Volterrani M, Lorusso R, Romanelli G, Giustina A. Acute growth hormone effects in human subjects with heart failure. In: Giustina A, editor. Growth Hormone and the Heart. Boston: Kluwer Academic; 2001. pp. 87–96.
    1. Napoli R, Guardasole V, Angelini V, D´Amico F, Zarra E, Matarazzo M, Saccà L. Acute effects of growth hormone on vascular function in human subjects. J. Clin. Endocrinol. Metab. 2003;88:2817–2820.
    1. Lembo G, Rockman HA, Hunter JJ, Steinmetz H, Koch WJ, Ma L, Prinz MP, Ross J, Jr, Chien KR, Powell-Braxton L. Elevated blood pressure and enhanced myocardial contractility in mice with severe IGF-1 deficiency. J. Clin. Invest. 1996;98:2648–2655.
    1. Tivesten Å, Bollano E, Andersson I, Fitzgerald S, Caidahl K, Sjögren K, Skøtt O, Liu J-L, LeRoith D, Mobini R, Isaksson OGP, Jansson J-O, Ohlsson C, Bergström G, Isgaard J. Liver-derived insulin-like growth factor-I is involved in the regulation of blood pressure in nice. Endocrinology. 2002;143:4235–4242.
    1. Tsukahara H, Gordienko DV, Tonshoff B, Gelato MC, Goligorsky MS. Direct demonstration of insulin-like growth factor-I-induced nitric oxide production by endothelial cells. Kidney Int. 1994;45:598–604.
    1. Muniyappa R, Walsh MF, Rangi JS, Zayas RM, Standley PR, Ram JL, Sowers JR. Insulin like growth factor 1 increases vascular smooth muscle nitric oxide production. Life Sci. 1997;61:925–931.
    1. Haylor J, Singh I, el Nahas AM. Nitric oxide synthesis inhibitor prevents vasodilation by insulin-like growth factor I. Kidney Int. 1991;39:333–335.
    1. Fryburg DA. NG-monomethyl-l-arginine inhibits the blood flow but not the insulin-like response of forearm muscle to IGF- I: possible role of nitric oxide in muscle protein synthesis. J. Clin. Invest. 1996;97:1319–1328.
    1. Oltman CL, Kane NL, Gutterman DD, Bar RS, Dellsperger KC. Mechanism of coronary vasodilation to insulin and insulin-like growth factor I is dependent on vessel size. Am. J. Physiol. Endocrinol. Metab. 2000;279:E176–E181.
    1. Hirschberg R, Kopple JD. Evidence that insulin-like growth factor I increases renal plasma flow and glomerular filtration rate in fasted rats. J. Clin. Invest. 1989;83:326–330.
    1. Hasdai D, Rizza RA, Holmes DR, Jr, Richardson DM, Cohen P, Lerman A. Insulin and insulin-like growth factor-I cause coronary vasorelaxation in vitro. Hypertension. 1998;32:228–234.
    1. Standley PR, Zhang F, Zayas RM, Muniyappa R, Walsh MF, Cragoe E, Sowers JR. IGF-I regulation of Na(+)-K(+)-ATPase in rat arterial smooth muscle. Am. J. Physiol. 1997;273:E113–E121.
    1. Tivesten Å, Barlind A, Caidahl K, Klintland N, Cittadini A, Ohlsson C, Isgaard J. J. Endocrinol. 2004;183:195–202.
    1. Fujita A, Kurachi Y. Molecular aspects of ATP sensitive K+ channels in the cardiovascular system and K+ channel openers. Pharmacol. Ther. 2000;85:39–53.
    1. Miki T, Suzuki M, Shibasaki T, Uemura H, Sato T, Yamaguchi K, Koseki H, Iwanaga T, Nakaya H, Seino S. Mouse model of prinzmetal angina by disruption of the inward rectifier Kir6.1. Nat. Med. 2002;8:466–472.
    1. Sverrisdottir Y, Elam M, Caidahl K, Söderling AS, Herlitz H, Johannsson G. The effect of growth hormone (GH) replacement therapy on sympathetic nerve hyperactivity in hypopituitary adults: a double-blind, placebo-controlled, crossover, short-term trial followed by long-term open GH replacement in hypopituitary adults. J. Hypertens. 2003;10:1905–1914.
    1. Rosén T, Edén S, Larsson G, Wilhelmsen L, Bengtsson B-Å. Cardiovascular risk factors in adult patients with growth hormone deficiency. Acta Endocrinol. 1993;129:195–200.
    1. Markussis V, Beshyah S, Fisher C, Sharp P, Nicolaides A, Johnston D. Detection of premature atherosclerosis by high-resolution ultrasonography in symptom-free hypopituitary adults. Lancet. 1992;340:1188–1192.
    1. Cittadini A, Cuocolo A, Merola B, Fazio S, Sabatini D, Nicolai E, Colao A, Longobardi S, Lombardi G, Sacca L. Impaired cardiac performance in GH-deficient adults and its improvement after GH replacement. Am. J. Physiol. 1994;267:E219–E225.
    1. Amato G, Carella C, Fazio S, La Montagna G, Cittadini A, Sabatini D, Marciano-Mone C, Sacca L, Bellastella A. Body composition, bone metabolism, and heart structure and function in growth hormone (GH)-deficient adults before and after GH replacement therapy at low doses. J. Clin. Endocrinol. Metab. 1993;77:1671–1676.
    1. Fazio S, Cittadini A, Sabatini D, Merola B, Colao A, Biondi B, Longobardi S, Lombardi G, Sacca L. Growth hormone and heart performance. A novel mechanism of cardiac wall stress regulation in humans. Eur. Heart J. 1997;18:340–347.
    1. Caidahl K, Edén S, Bengtsson B-Å. Cardiovascular and renal effects of growth hormone. Clin. Endocrinol. 1994;40:93–400.
    1. Johannsson G, Mårin P, Lönn L, Ottosson M, Stenlöf K, Björntorp P, Sjöström L, Bengtsson B-Å. GH treatment of abdominally obese men reduces abdominal fat mass, improves glucose and lipoprotein metabolism, and reduces diastolic blood pressure. J. Clin. Endocrinol. Metab. 1997;82:727–734.
    1. Böger R, Skamira C, Bode-Böger S, Brabant G, von zur Mühlen A, Frölich J. Nitric oxide may mediate the hemodynamic effects of recombinant growth hormone in patients with acquired growth hormone deficiency. J. Clin. Invest. 1996;98:2706–2713.
    1. Götherström G, Svensson J, Koranyi J, Alpsten M, Bosæus I, Bengtsson B-Å, Johannsson G. A prospective study of five years of growth hormone (GH) replacement therapy in GH deficient adults; sustained effects on body composition, bone mass, and metabolic indices. J. Clin. Endocrinol. Metab. 2001;86:4657–4665.
    1. ter Maaten J, de Boer H, Kamp O, Stuurman L, van der Veen E. Long-term effects of growth hormone (GH) replacement in men with childhood-onset GH deficiency. J. Clin. Endocrinol. Metab. 1999;84:2373–2380.
    1. Johannsson G, Sunnerhagen K, Svensson J. Baseline characteristics and the effects of two years of growth hormone (GH) replacement therapy in adults with GH deficiency previously treated for Cushing´s disease. Clin. Endocrinol. 2004;60:550–559.
    1. Borson-Chazot F, Serusclat A, Kalfallah Y, Ducottet X, Sassolas G, Bernard S, Labrousse F, Pastene J, Sassolas A, Roux Y, Berthezene F. Decrease in carotid intima-media thickness after one year growth hormone (GH) treatment in adults with GH deficiency. J. Clin. Endocrinol. Metab. 1999;84:1329–1333.
    1. Pfeifer M, Verhovec M, Zizek B, Prezelj J, Poredos P, Clayton RN. Growth hormone (GH) treatment reverses early atherosclerotic changes in GH-deficient adults. J. Clin. Endocrinol. Metab. 1999;84:453–457.
    1. Penney DG, Dunbar JC, Jr, Baylerian MS. Cardiomegaly and haemodynamics in rats with a transplantable growth hormone-secreting tumour. Cardiovasc. Res. 1985;19:270–277.
    1. Bohlooly YM, Carlson L, Olsson B, Gustafsson H, Andersson IJ, Törnell J, Bergström G. Vascular function and blood pressure in GH transgenic mice. Endocrinology. 2001;142:3317–3323.
    1. Losa M, von Werder K. The heart in acromegaly. In: Giustina A, editor. Growth Hormone and the Heart. Boston: Kluwer Academic; 2001. pp. 33–43.
    1. Mosca S, Paolillo S, Colao A, Bossone E, Cittadini A, Ludice FL, Parente A, Conte S, Rengo G, Leosco D, Trimarco B, Filardi PP. Cardiovascular involvement in patients affected by acromegaly: an appraisal. Int. J. Cardiol. 2013;167:1712–1718.
    1. Bogazzi F, Battolla L, Spinelli C, Rossi G, Gavioli S, Di Bello V, Cosci C, Sardella C, Volterrani D, Talini E, Pepe P, Falaschi F, Mariani G, Martino E. Risk factors for development of coronary artery disease in patients with acromegaly: a five-year prospective study. J. Clin. Endocrinol. Metab. 2007;92:4271–4277.
    1. Akutsu H, Kreutzer J, Wasmeier G, Ropers D, Rost C, Möhlig M, Wallaschofski H, Buchfelder M, Schöfl C. Acromegaly per se does not increase the risk for coronary artery disease. Eur. J. Endocrinol. 2010;162:879–886.
    1. Otsuki M, Kasayama S, Yamamoto H, Saito H, Sumitani S, Kouhara H, Saitoh Y, Ohnishi T, Arita N. Characterization of premature atherosclerosis of carotid arteries in acromegalic patients. Clin. Endocrinol. 2001;54:791–796.
    1. Verhelst J, Velkeniers B, Maiter D, Haentjens P, T´Sjoen G, Rietzschel G, Corvilain B, Abrams P, Nobels F, Abs R, Bex M. Active acromegaly is associated with decreased hs-CRP and NT-proBNP serum levels: insights from the Belgian registry of acromegaly. Eur. J. Endocrinol. 2013;168:177–184.
    1. Donath MY, Zapf J, Eppenberger-Eberhardt M, Froesch ER, Eppenberger HM. Insulin-like growth factor I stimulates myofibril development and decreases smooth muscle alpha-actin of adult cardiomyocytes. Proc. Natl. Acad. Sci. USA. 1994;91:1686–1690.
    1. Ito H, Hiroe M, Hirata Y, Tsujino M, Adachi S, Shichiri M, Koike A, Nogami A, Marumo F. Insulin-like growth factor-I induces hypertrophy with enhanced expression of muscle specific genes in cultured rat cardiomyocytes. Circulation. 1993;87:1715–1721.
    1. Schnabel P, Mies F, Nohr T, Geisler M, Bohm M. Differential regulation of phospholipase C-beta isozymes in cardiomyocyte hypertrophy. Biochem. Biophys. Res. Commun. 2000;275:1–6.
    1. Lu C, Schwartzbauer G, Sperling MA, Devaskar SU, Thamotharan S, Robbins PD, McTiernan CF, Liu JL, Jiang J, Frank SJ, Menon RK. Demonstration of direct effects of growth hormone on neonatal cardiomyocytes. J. Biol. Chem. 2001;276:22892–22900.
    1. Fuller SJ, Mynett JR, Sugden PH. Stimulation of cardiac protein synthesis by insulin-like growth factors. Biochem. J. 1992;282(Pt 1):85–90.
    1. Donath MY, Gosteli-Peter MA, Hauri C, Froesch ER, Zapf J. Insulin-like growth factor-I stimulates myofibrillar genes and modulates atrial natriuretic factor mRNA in rat heart. Eur. J. Endocrinol. 1997;137:309–315.
    1. Musaro A, McCullagh KJ, Naya FJ, Olson EN, Rosenthal N. IGF-1 induces skeletal myocyte hypertrophy through calcineurin in association with GATA-2 and NF-ATc1. Nature. 1999;400:581–585.
    1. Creemers EE, Cleutjens JP, Smits JF, Daemen MJ. Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure? Circ. Res. 2001;89:201–210.
    1. Butt RP, Laurent GJ, Bishop JE. Collagen production and replication by cardiac fibroblasts is enhanced in response to diverse classes of growth factors. Eur. J. Cell Biol. 1995;68:330–335.
    1. Bruel A, Oxlund H. Biosynthetic growth hormone increases the collagen deposition rate in rat aorta and heart. Eur. J. Endocrinol. 1995;132:195–199.
    1. Cittadini A, Stromer H, Katz SE, Clark R, Moses AC, Morgan JP, Douglas PS. Differential cardiac effects of growth hormone and insulin-like growth factor-1 in the rat. A combined in vivo and in vitro evaluation. Circulation. 1996;93:800–809.
    1. Bruel A, Oxlund H, Nyengaard JR. Growth hormone increases the total number of myocyte nuclei in the left ventricle of adult rats. Growth Horm. IGF Res. 2002;12:106–115.
    1. Kajstura J, Cheng W, Sarangarajan R, Li P, Li B, Nitahara JA, Chapnick S, Reiss K, Olivetti G, Anversa P. Necrotic and apoptotic myocyte cell death in the aging heart of Fischer 344 rats. Am. J. Physiol. 1996;271:H1215–H1228.
    1. Li Q, Li B, Wang X, Leri A, Jana KP, Liu Y, Kajstura J, Baserga R, Anversa P. Overexpression of insulin-like growth factor-1 in mice protects from myocyte death after infarction, attenuating ventricular dilation, wall stress, and cardiac hypertophy. J. Clin. Invest. 1997;100:1991–1999.
    1. Buerke M, Murohara T, Skurk C, Nuss C, Tomaselli K, Lefer AM. Cardioprotective effect of insulin-like growth factor I in myocardial ischemia followed by reperfusion. Proc. Natl. Acad. Sci. USA. 1995;92:8031–8035.
    1. Reiss K, Cheng W, Ferber A, Kajstura J, Li P, Li B, Olivetti G, Homcy CJ, Baserga R, Anversa P. Overexpression of insulin-like growth factor-1 in the heart is coupled with myocyte proliferation in transgenic mice. Proc. Natl. Acad. Sci. USA. 1996;93:8630–8635.
    1. Longobardi S, Cuocolo A, Merola B, Di Rella F, Colao A, Nicolai E, Cardei S, Salvatore M, Lombardi G. Left ventricular function in young adults with childhood and adulthood onset growth hormone deficiency. Clin. Endocrinol. 1998;48:137–143.
    1. Cuneo R, Salomon F, Wiles C, Hesp R, Sönksen P. Growth hormone treatment in growth hormone-deficient adults. II. Effects on exercise performance. J. Appl. Physiol. 1991;70:695–700.
    1. Beshyah S, Shahi M, Skinner E, Sharp P, Foale R, Johnston D. Cardiovascular effects of growth hormone replacement therapy in hypopituitary adults. Eur. J. Endocrinol. 1994;130:451–458.
    1. Fort S, Weaver J, Monson J, Mills P. The effects of low dose recombinant human growth hormone on cardiovascular structure and function in hypopituitary adults growth hormone-deficient adults. Endocrinol. Metab. 1995;2:119–126.
    1. Thuesen L, Jørgensen J, Müller J, Kristensen B, Skakkebæk N, Vahl N, Christiansen JS. Short and long-term cardiovascular effects of growth hormone therapy in growth hormone deficient adults. Clin. Endocrinol. 1994;41:615–620.
    1. Johannsson G, Bengtsson B-Å, Andersson B, Isgaard J, Caidahl K. Long-term cardiovascular effects of growth hormone treatment in GH-deficient adults. Preliminary data in a small group of patients. Clin. Endocrinol. 1996;45:305–314.
    1. Saccà L, Napoli R, Cittadini A. Growth hormone, acromegaly and heart failure: an intricate triangulation. Clin. Endocrinol. 2003;59:660–671.
    1. Bollano E, Omerovic E, Bohlooly-y M, Kujacic V, Madhu B, Tornell J, Isaksson O, Soussi B, Schulze W, Fu ML, Matejka G, Waagstein F, Isgaard J. Impairment of cardiac function and bioenergetics in adult transgenic mice overexpressing the bovine growth hormone gene. Endocrinology. 2000;141:2229–2235.
    1. Vetter U, Kupferschmid C, Lang D, Pentz S. Insulin-like growth factors and insulin increase the contractility of neonatal rat cardiocytes in vitro. Basic Res. Cardiol. 1988;83:647–654.
    1. Freestone NS, Ribaric S, Mason WT. The effect of insulin-like growth factor-1 on adult rat cardiac contractility. Mol. Cell. Biochem. 1996;163–164:223–229.
    1. Cittadini A, Ishiguro Y, Strömer H, Spindler M, Moses AC, Clark R, Douglas PS, Ingwall JS, Morgan JP. Insulin-like growth factor-1 but not growth hormone augments mammalian myocardial contractility by sensitizing the myofilament to Ca2+ through a wortmannin-sensitive pathway: studies in rat and ferret isolated muscles. Circ. Res. 1998;83:50–59.
    1. Strömer H, Cittadini A, Douglas PS, Morgan JP. Exogenously administered growth hormone and insulin-like growth factor-I alter intracellular Ca2+ handling and enhance cardiac performance. In vitro evaluation in the isolated isovolumic buffer-perfused rat heart. Circ. Res. 1996;79:227–236.
    1. Tajima M, Weinberg EO, Bartunek J, Jin H, Yang R, Paoni NF, Lorell BH. Treatment with growth hormone enhances contractile reserve and intracellular calcium transients in myocytes from rats with postinfarction heart failure. Circulation. 1999;99:127–134.
    1. Cittadini A, Strömer H, Vatner DE, Grossman JD, Katz SE, Clark R, Morgan JP, Douglas PS. Consequences of growth hormone deficiency on cardiac structure, function, and beta-adrenergic pathway: studies in mutant dwarf rats. Endocrinology. 1997;138:5161–5169.
    1. Strömer H, Cittadini A, Grossman JD, Douglas PS, Morgan JP. Intrinsic cardiac muscle function, calcium handling and beta -adrenergic responsiveness is impaired in rats with growth hormone deficiency. Growth Horm. IGF Res. 1999;1999(9):262–271.
    1. Ren J, Brown-Borg H. Impaired cardiac excitation-contraction coupling in ventricular myocytes from Ames dwarf mice with IGF-I deficiency. Growth Horm. IGF Res. 2002;12:99–105.
    1. Kinugawa S, Tsutsui H, Ide T, Nakamura R, Arimura K, Egashira K, Takeshita A. Positive inotropic effect of insulin-like growth factor-1 on normal and failing cardiac myocytes. Cardiovasc. Res. 1999;43:157–164.
    1. Solem ML, Thomas AP. Modulation of cardiac Ca2+ channels by IGF-1. Biochem. Biophys. Res. Commun. 1998;252:151–155.
    1. Xu XP, Best PM. Decreased transient outward K+ current in ventricular myocytes from acromegalic rats. Am. J. Physiol. 1991;260:H935–H942.
    1. Houck WV, Pan LC, Kribbs SB, Clair MJ, McDaniel GM, Krombach RS, Merritt WM, Pirie C, Iannini JP, Mukherjee R, Spinale FG. Effects of growth hormone supplementation on left ventricular morphology and myocyte function with the development of congestive heart failure. Circulation. 1999;100:2003–2009.
    1. Jin H, Yang R, Lu H, Ogasawara AK, Li W, Ryan A, Peale F, Paoni NF. Effects of early treatment with growth hormone on infarct size, survival, and cardiac gene expression after acute myocardial infarction. Growth Horm. IGF Res. 2002;12:208–215.
    1. Ueyama T, Ohkusa T, Yano M, Matsuzaki M. Growth hormone preserves cardiac sarcoplasmic reticulum Ca2+ release channels (ryanodine receptors) and enhances cardiac function in cardiomyopathic hamsters. Cardiovasc. Res. 1998;40:64–73.
    1. Mayoux E, Ventura-Clapier R, Timsit J, Behar-Cohen F, Hoffmann C, Mercadier JJ. Mechanical properties of rat cardiac skinned fibers are altered by chronic growth hormone hypersecretion. Circ. Res. 1993;72:57–64.
    1. Timsit J, Riou B, Bertherat J, Wisnewsky C, Kato NS, Weisberg AS, Lubetzki J, Lecarpentier Y, Winegrad S, Mercadier JJ. Effects of chronic growth hormone hypersecretion on intrinsic contractility, energetics, isomyosin pattern, and myosin adenosine triphosphatase activity of rat left ventricle. J. Clin. Invest. 1990;86:507–515.
    1. Johansson J-O, Fowelin J, Landin K, Lager I, Bengtsson B-Å. Growth hormone-deficient adults are insulin-resistant. Metabolism. 1995;44:1126–1129.
    1. Hew F, Koschmann M, Christopher M, Rantzau C, Vaag A, Ward G, Beck-Nielsen H, Alford F. Insulin resistance in growth hormone-deficient adults: defects in glucose utilization and glycogen synthase activity. J. Clin. Endocrinol. Metab. 1996;81:555–564.
    1. Drake W, Howell S, Monson J, Shalet S. Optimizing GH therapy in adults and children. Endocr. Rev. 2001;22:425–450.
    1. Johansson J-O, Landin K, Tengborn L, Rosén T, Bengtsson B-Å. High fibrinogen and plasminogen activator inhibitor activity in growth hormone-deficient adults. Arterioscler. Thromb. 1994;14:434–437.
    1. Gola M, Bonadonna S, Doga M, Giustina A. Clinical review. Growth hormone and cardiovascular risk factors. J. Clin. Endocrinol. Metab. 2005;90(3):1864–1870.
    1. Li L, Ren W, Li J. Increase in serum pregnancy-associated plasma protein-A is correlated with increase in cardiovascular risk factors in adult patients with growth hormone deficiency. Endocrine. 2012;42(2):375–381.
    1. Rosén T, Bosaeus I, Tölli J, Lindstedt G, Bengtsson B-Å. Increased body fat mass and decreased extracellular fluid volume in adults with growth hormone deficiency. Clin. Endocrinol. 1993;38:63–71.
    1. Juul A, Hjortskov N, Jepsen L, Nielsen B, Halkjaer-Kristensen J, Vahl N, Jørgensen JO, Christiansen JS, Skakkebaek N. Growth hormone deficiency and hyperthermia during exercise: a controlled study of sixteen GH-deficient patients. J. Clin. Endocrinol. Metab. 1995;80:3335–3340.
    1. Gazzaruso C, Gola M, Karamouzis I, Giubbini R, Giustina A. Cardiovascular risk in adult patients with growth hormone (GH) deficiency and following substitution with GH: an update. J. Clin. Endocrinol. Metab. 2014;99(1):18–29.
    1. Elbornsson M, Götherström G, Bosaeus I, Bengtsson B-Å, Johannsson G, Svensson J. Fifteen years of growth hormone replacement improves body composition and cardiovascular risk factors. Eur. J. Endocrinol. 2013;168:745–753.
    1. Johansson J-O, Landin K, Johannsson G, Tengborn L, Bengtsson B-Å. Long-term treatment with growth hormone decreases plasminogen activator inhibator-I and tissue plasminogen activator in growth hormone-deficient adults. Thromb. Haemost. 1996;76:422–428.
    1. Christopher M, Hew F, Oakley M, Rantzau C, Alford F. Defects of insulin action and skeletal muscle glucose metabolism in growth hormone-deficient adults persist after 24 months of recombinant human growth hormone therapy. J. Clin. Endocrinol. Metab. 1998;83:1668–1681.
    1. Svensson J, Fowelin J, Landin K, Bengtsson B-Å, Johansson J-O. Effects of 7 years of GH-replacement therapy on insulin sensitivity in GH-deficient adults. J. Clin. Endocrinol. Metab. 2002;87:2121–2127.
    1. Bülow B, Hagmar L, Mikoczy Z, Nordström C, Erfurth E. Increased cerebrovascular mortality in patients with hypopituitarism. Clin. Endocrinol. 1997;46:75–81.
    1. Bates A, Van´t Hoff W, Jones P, Clayton R. The effect of hypopituitarism on life expectancy. J. Clin. Endocrinol. Metab. 1996;81:1169–1172.
    1. Tomlinson J, Holden N, Hills R, Wheatley K, Clayton R, Bates A, Sheppard M, Stewart P. Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group. Lancet. 2001;357:425–431.
    1. Svensson J, Bengtsson B-Å, Rosén T, Odén A, Johannson G. The incidence of malignant disease and cardiovascular morbidity in hypopituitary patients with or without growth hormone replacement therapy. J. Clin. Endocrinol. Metab. 2004;89:3306–3312.
    1. Hartman M, Xu R, Crowe BJ, Robison LL, Erfurth EM, Kleinberg DL, Zimmermann AG, Woodmansee WW, Cutler GB, Jr, Chipman JJ, Melmed SS. International HypoCCS Advisory Board: prospective safety surveillance of GH-deficient adults: comparison of GH-treated vs untreated patients. J. Clin. Endocrinol. Metab. 2013;98:980–988.
    1. Yang R, Bunting S, Gillett N, Clark R, Jin H. Growth hormone improves cardiac performance in experimental heart failure. Circulation. 1995;92:262–267.
    1. Isgaard J, Kujacic V, Jennische E, Holmäng A, Sun XY, Hedner T, Hjalmarson Å, Bengtsson B-Å. Growth hormone improves cardiac function in rats with experimental myocardial infarction. Eur. J. Clin. Invest. 1997;27:517–525.
    1. Jin H, Yang R, Gillett N, Clark RG, Ko A, Paoni NF. Beneficial effects of growth hormone and insulin-like factor-1 in experimental heart failure in rats treated with chronic ACE inhibition. J. Cardiovasc. Pharmacol. 1995;26:420–425.
    1. Omerovic E, Fahrami R, Basetti M, Soussi B, Hjalmarson Å, Waagstein F, Isgaard J. Growth hormone improves bioenergetics and decreases catecholamines in postinfarct rat hearts. Endocrinology. 2000;141:4592–4599.
    1. Cittadini A, Isgaard J, Monti MG, Casaburi C, Di Gianni AD, Serpico R, Saccà L. Growth hormone prolongs survival and attenuates interstitial remodeling in postinfarction heart failure. J. Am. Coll. Cardiol. 2003;41:2154–2163.
    1. Cuneo RC, Wilmshurst P, Lowy C, McGauley G, Sönksen PH. Cardiac failure responding to growth hormone. Lancet. 1989;1:838–839.
    1. Frustaci A, Perrone GA, Gentiloni N, Russo MA. Reversible dilated cardiomyopathy due to growth hormone deficiency. Am. J. Clin. Pathol. 1992;97:503–511.
    1. Fazio S, Sabatini D, Capaldo B, Vigorito C, Giordano A, Guida R, Pardo F, Biondi B, Sacca L. A preliminary study of growth hormone in the treatment of dilated cardiomyopathy. N. Engl. J. Med. 1996;334:809–814.
    1. Genth-Zotz S, Zotz R, Geil S, Voigtlander T, Meyer J, Darius H. Recombinant growth hormone therapy in patients with ischemic cardiomyopathy. Effects on hemodynamics, left ventricular function and cardiopulmonary exercise capacity. Circulation. 1999;99:18–21.
    1. Volterrani M, Desenzani P, Lorusso R, d’Aloia A, Manelli F, Giustina A. Haemodynamic effects of intravenous growth hormone in congestive heart failure. Lancet. 1997;349:1067–1068.
    1. Giustina A, Volterrani M, Manelli F, Desenzani P, Poiesi C, Lorusso R, Giordano A. Endocrine predictors of acute hemodynamic effects of growth hormone in congestive heart failure. Am. Heart J. 1999;137(6):1035–1043.
    1. Adamopoulos S, Parissis JT, Georgiadis M, Karatzas D, Paraskevaid I, Kroupis C, Karavolias G, Koniavitou K, Kremastinos DT. Growth hormone administration reduces circulating proinflammatory cytokines and soluble Fas/soluble Fas ligand system in patients with chronic heart failure secondary to idiopathic dilated cardiomyopathy. Am. Heart J. 2002;144:359–364.
    1. Napoli R, Guardasole V, Matarazzo M, Palmieri EA, Oliviero U, Fazio S, Sacca L. Growth hormone corrects vascular dysfunction in patients with chronic heart failure. J. Am. Coll. Cardiol. 2002;39:90–95.
    1. Osterziel KJ, Strohm O, Schuler J, Friedrich M, Hanlein D, Willenbrock R, Anker SD, Poole-Wilson PA, Ranke MB, Dietz R. Randomised, double-blind, placebo-controlled trial of human recombinant growth hormone in patients with chronic heart failure due to dilated cardiomyopathy. Lancet. 1998;351:1233–1237.
    1. Isgaard J, Bergh CH, Caidahl K, Lomsky M, Hjalmarson A, Bengtsson BÅ. A placebo-controlled study of growth hormone in patients with congestive heart failure. Eur. Heart J. 1998;19:1704–1711.
    1. Perrot A, Ranke MB, Dietz R, Osterziel KJ. Growth hormone treatment in dilated cardiomyopathy. J. Card. Surg. 2001;16:127–131.
    1. Acevedo M, Corbalán R, Chamorro G, Jalil J, Nazzal C, Campusano C, Castro P. Administration of growth hormone to patients with advanced cardiac heart failure: effects upon left ventricular function, exercise capacity and neurohormonal status. Int. J. Cardiol. 2003;87:185–191.
    1. Christensen HM, Kistorp C, Schou M, Keller N, Zerahn B, Frystyk J, Schwarz P, Faber J. Prevalence of cachexia in chronic heart failure and characteristics of body composition and metabolic status. Endocrine. 2013;43(3):626–634.
    1. Mangner N, Matsuo Y, Schuler G, Adams V. Cachexia in chronic heart failure: endocrine determinants and treatment perspectives. Endocrine. 2013;43:253–265.
    1. Anker SD, Volterrani M, Pflaum CD, Strasburger CJ, Osterziel KJ, Doehner W, Ranke MB, Poole-Wilson PA, Giustina A, Dietz R, Coats AJ. Acquired growth hormone resistance in patients with chronic heart failure: implications for therapy with growth hormone. J. Am. Coll. Cardiol. 2001;38:443–452.
    1. Le Corvoisier P, Hittinger L, Chanson P, Montagne O, Macquin-Mavier I, Maison P. Cardiac effects of growth hormone treatment in chronic heart failure: a meta-analysis. J. Clin. Endocrinol. Metab. 2007;92:180–185.
    1. Sacca L. Heart failure as a multiple hormonal deficiency syndrome. Circ Heart Fail. 2009;2:151–156.
    1. Jankowska EA, Biel B, Majda J, Szklarska A, Lopuszanska M, Medras M, Anker SD, Banasiak W, Poole-Wilson PA, Ponikowski P. Anabolic deficiency in men with chronic heart failure: prevalence and detrimental impact on survival. Circulation. 2006;114:1829–1837.
    1. Volterrani M, Rosano G, Iellamo F. Testosterone and heart failure. Endocrine. 2012;42(2):272–277.
    1. Broglio F, Benso A, Gottero C, Vito LD, Aimaretti G, Fubini A, Arvat E, Bobbio M, Ghigo E. Patients with dilated cardiomyopathy show reduction of the somatotroph responsiveness to GHRH both alone and combined with arginine. Eur. J. Endocrinol. 2000;142:157–163.
    1. Kontoleon PE, Anastasiou-Nana MI, Papapetrou PD, Alexopoulos G, Ktenas V, Rapti AC, Tsagalou EP, Nanas JN. Hormonal profile in patients with congestive heart failure. Int. J. Cardiol. 2003;87:179–183.
    1. Watanabe S, Tamura T, Ono K, Horiuchi H, Kimura T, Kita T, Furukawa Y. Insulin-like growth factor axis (insulin-like growth factor-I/insulin-like growth factor-binding protein-3) as a prognostic predictor of heart failure: association with adiponectin. Eur. J. Heart Fail. 2010;12:1214–1222.
    1. Giustina A, Lorusso R, Borghetti V, Bugari G, Misitano V, Alfieri O. Impaired spontaneous growth hormone secretion in severe dialated cardiomyopathy. Am. Heart J. 1996;131:620–622.
    1. Cittadini A, Saldamarco L, Marra AM, Arcopinto M, Carlomagno G, Imbriaco M, Del Forno D, Vigorito C, Merola B, Oliviero U, Fazio S, Sacca L. Growth hormone deficiency in patients with chronic heart failure and beneficial effects of its correction. J. Clin. Endocrinol. Metab. 2009;94:3329–3336.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir